Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.2896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Fangzheng Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cardiovascular Diseases, Phenylurea Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs) and anti‐angiogenics, are first‐line therapies for advanced and metastatic hepatocellular carcinoma. Although TKIs have a greater potential for off‐target adverse effects compared with bevacizumab (anti‐angiogenics), a direct comparison of the risk of cardiovascular adverse events between these two types of therapies has not been performed.
Objective
To compare the incidence of and characterize cardiovascular adverse events in patients with hepatocellular carcinoma receiving TKIs versus bevacizumab.
Methods
This cohort study included adult patients with hepatocellular carcinoma who received first‐line TKIs (sorafenib or lenvatinib) or bevacizumab at two academic medical centers and one community cancer center from September 2018 to August 2021. The primary outcome was risk of cardiovascular adverse events. Major secondary outcomes included the incidence of individual types of cardiovascular adverse events and risk factors associated with major adverse cardiovascular events (MACE).
Results
The study included 221 patients (159 TKI patients; 62 bevacizumab patients). At a median follow‐up of 5 months, the probability of cardiovascular adverse events was not significantly different between the two groups (hazard ratio [HR]: 0.85; 95% confidence interval [95% CI]: 0.58–1.24; p = 0.390). The cumulative incidence of cardiovascular events was highest in patients receiving lenvatinib (sub‐distribution hazard ratio [SHR]: 1.53; 95% CI: 1.02–2.30) compared with those receiving sorafenib (reference) or bevacizumab (SHR: 1.05; 95% CI: 0.68–1.64) after adjustment for comorbidities, liver transplant status, and presence of portal vein thrombosis at baseline. Cardiovascular adverse events were observed in 151 (68%) patients, and MACE were observed in 27 (12%) patients. Risk factors associated with MACE were hypertension (SHR: 3.5; 95% CI: 0.9087–15.83; p = 0.086), prior history of MACE (SHR: 2.01; 95% CI: 0.83–4.87; p = 0.124), and tobacco use (SHR: 2.85; 95% CI: 0.90–8.97; p = 0.074).
Conclusions
Cardiovascular risk was not significantly different between TKIs and bevacizumab. Lenvatinib appears to have the highest risk of cardiovascular adverse events among these first‐line VEGF inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA.
- Department of Research, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
- Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
- Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Fangzheng Yuan, Ronald Krone, Grant R Williams, Darryl Outlaw, Michael Katsnelson, Stephen Lirette
Förderung
- NHLBI NIH HHS
Zitieren
APA
Yuan, F., Lenneman, C., Krone, R., Williams, G. R., Outlaw, D., Katsnelson, M., & Lirette, S. (2024). Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2896
Vancouver
Yuan F, Lenneman C, Krone R, Williams GR, Outlaw D, Katsnelson M, et al. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2896
BibTeX
@article{Yuan2024,
author = {Yuan, Fangzheng and Lenneman, Carrie and Krone, Ronald and Williams, Grant R and Outlaw, Darryl and Katsnelson, Michael and Lirette, Stephen},
title = {Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.2896}
}
EUVIMED